Skip to main
HYPR

Hyperfine (HYPR) Stock Forecast & Price Target

Hyperfine (HYPR) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Hyperfine is a promising medical device company with a unique position in the market through their AI-powered portable MRI system, Swoop. Their expanding international presence and potential market growth in the neurology office market show positive momentum. With a strong management team, cost-saving technology, and high market valuation, Hyperfine's stock is likely to continue to perform well despite potential risks.

Bears say

Hyperfine is a medical device company with a negative outlook due to potential future challenges in the market, such as supplier pricing pressure and competition, as well as the company's current financials of high cash burn and limited profitability. Additionally, there is a risk of delay in reaching commercial milestones and the potential need for additional funding. While the company has a first-mover advantage in the portable MRI market and has demonstrated success with its Swoop system, there are still regulatory and commercial hurdles to overcome, and other players may enter the market with competitive products.

Hyperfine (HYPR) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hyperfine and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hyperfine (HYPR) Forecast

Analysts have given Hyperfine (HYPR) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Hyperfine (HYPR) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.03, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.03, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hyperfine (HYPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.